Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 28, 2015

Primary Completion Date

July 31, 2017

Study Completion Date

November 30, 2017

Conditions
Subclinical Acute Antibody-mediated Rejection in Kidney Transplantation
Interventions
DRUG

Eculizumab

"Eculizumab induction: 900 mg IV every 7 days for 4 doses, a fifth 1200 mg dose 7 days later Eculizumab maintenance: 15 1200 mg doses every 14 days.~(each patient will receive a total of 20 eculizumab doses during the whole treatment period from 3 month to 12 month post-transplant)."

Sponsors
All Listed Sponsors
collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

collaborator

Alexion Pharmaceuticals, Inc.

INDUSTRY

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT02113891 - Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation | Biotech Hunter | Biotech Hunter